Is mTOR Pathway Activity a Good Predictor for Everolimus Therapy? A Pilot Study to Build Up a Phase II Trial in Pancreatic Neuroendocrine Neoplasias (pNENs) Abstract #1524

Introduction: Everolimus (EVE) is an approved treatment for progressive well-differentiated pNENs and usually induces stable disease. Until now, there is no reliable biomarker for the response to EVE.
Aim(s): To study mTOR pathway activation as a new discriminator for EVE therapy.
Materials and methods: FFPE tumor material of 60 pNEN patients from 4 centers was macrodissected and RNA was extracted. Upregulation of 12 mTOR pathway signaling members was studied by TaqMan based RT-qPCR assays. Relative gene expression was determined according to the 40-DCT method using CALM2 as housekeeping gene.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: PD Dr. Patricia Grabowski

To read results and conclusion, please login ...

Further abstracts you may be interested in

#167 Localization of Sporadic Neuroendocrine Tumors by Gene expression Analysis of Their Metastases
Introduction: Primary neuroendocrine tumors (NETs) are rare and often difficult to detect, leading to diagnosis late in their development. Cases in which the primary cannot be located are denoted as CUP-Syndrome.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dipl. Biol. Nicole Posorski
#1032 Clinico-Biological and Histological Predictive Factors and Markers of Response to Everolimus in Neuroendocrine Tumors
Introduction: Several systemic treatments are available for metastatic neuroendocrine Tumors (NETs), including everolimus, but there is no predictive factor of response to these treatments.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Noura Benslama
#1557 Dual High Throughput Proteomic and Transcriptomic Screen for Predictive Biomarkers of Everolimus Sensitivity in Pancreatic NET
Introduction: mTOR inhibitor Everolimus is approved for the treatment of well-differentiated PNET. The heterogeneity of the response rate and the potential toxicity warrant predictive biomarkers.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Jerome Cros
Authors: Bucau M, Cros J, Raffenne J, Rebours V, ...
#852 5-FU-based Chemotherapy in Pancreatic Neuroendocrine Neoplasms: Predictive and Prognostic Markers for Treatment und Survival
Introduction: Chemotherapy with 5-FU and Streptozotocin (STZ) represents a standard of care for patients with metastatic pancreatic neuroendocrine neoplasms (PNENs). However, data to identify predictive and prognostic markers are limited.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: M.D. Sebastian Krug
Authors: Krug S, Boch M, Rinke A, Nimphius W, ...
Keywords: 5-fluorouracil, DPD, PNEN
#1007 Normal Tissue Perfusion Changes During Everolimus Treatment: Preliminary Results from a Functional Vascular Study
Introduction: Everolimus (E) acts on cancer progression, even inhibiting tumor angiogenesis. Both tumor vasculature and a normal one could undergo everolimus effect.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Sara Cingarlini